SeaStar Medical Holding Corporation (ICU)
After hours:
| Previous close | 0.4818 |
| Open | 0.4887 |
| Bid | 0.4382 x 200 |
| Ask | 0.4504 x 400 |
| Day's range | 0.4367 - 0.4887 |
| 52-week range | 0.1620 - 2.2700 |
| Volume | |
| Avg. volume | 5,439,419 |
| Market cap | 33.2M |
| Beta (5Y monthly) | -1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2100 |
| Earnings date | 14 May 2024 - 18 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.00 |
GlobeNewswireSeaStar Medical Reports 2023 Financial Results and Provides a Business Update
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update. “It was exceptionally exciting to receive our first FDA approval for Quelimmune™, which is now available for treating critically
- GlobeNewswire
SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time. The formal presentation will be followed by a hosted question-and-answer session. Investors int
- GlobeNewswire
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it will restate its financial statements for the fiscal year ended December 31, 2022 and for the interim periods ended March 31, 2023, June 30, 2023 and Sep
